Sign In
Buy PCRX
$26.41
-0.560 (-2.08%)
At Close: Jul 31, 2026
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
04:01pm, Wednesday, 26'th Nov 2025
-- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to de
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $33.00 Average PT from Analysts
02:34am, Tuesday, 18'th Nov 2025
Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX - Get Free Report) have earned a consensus recommendation of "Hold" from the seven analysts that are covering the company, MarketBeat reports. One equi
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
08:00am, Tuesday, 11'th Nov 2025
BRISBANE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv
DOMA Controls 6.8% of Pacira Common Stock MIAMI , Nov. 10, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira"),
Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript
06:16am, Friday, 07'th Nov 2025
Pacira BioSciences, Inc. ( PCRX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Susan Mesco - Head of Investor Relations Frank Lee - CEO & Director Brendan Teehan - Chief Com
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
04:01pm, Thursday, 06'th Nov 2025
-- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBAN
-- Milestone advances two-part study evaluating novel, locally administered gene therapy designed to increase anti-inflammatory IL-1Ra production in the knee joint -- BRISBANE, Calif., Nov. 05, 2025 (
-- Advances 5x30 strategy by expanding pipeline with a highly complementary asset that has the potential to provide several days of pain control -- -- Phase 2 program for AMT-143 expected to begin i
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
08:00am, Thursday, 30'th Oct 2025
BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv
Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Wednesday, 29'th Oct 2025
Pacira (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
08:00am, Monday, 27'th Oct 2025
BRISBANE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv
Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®
08:00am, Thursday, 23'rd Oct 2025
-- Findings Presented at AMCP Nexus 2025 Annual Meeting -- BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovativ
Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Tuesday, 21'st Oct 2025
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®
08:30am, Tuesday, 21'st Oct 2025
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv
-- Poster to be presented at American College of Rheumatology Convergence 2025 – BRISBANE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in i
